非小细胞肺癌患者血清半胱氨酸蛋白酶抑制剂C的变化及意义

目的探讨非小细胞肺癌（NSCLC）患者血清中半胱氨酸蛋白酶抑制剂C（Cys C）的水平及其在肿瘤发生发展过程中的意义。方法采用酶联免疫吸附法（ELISA）测定102例NSCLC患者、60例良性肺部疾病患者和90例健康体检者血清Cys C水平,并进行比较分析。结果肺癌患者血清Cys C的水平明显高于良性肺疾病组和健康对照组[（1.47±0.78）mg/L比（1.04±0.51）mg/L和（1.06±0.36）mg/L,P〈0.01]。随着肿瘤的发展,患者血清Cys C的含量逐渐上升,无淋巴结转移低于有淋巴结转移[（1.06±0.39）mg/L比（1.83±0.97）mg/L,P〈0.05],TNM分期Ⅰ~Ⅱ期低于Ⅲ~Ⅳ期[（1.38±0.88）mg/L比（1.57±0.79）mg/L,P〈0.05]。中高分化肺癌血清Cys C的含量高于低分化肺癌[（1.63±0.73）mg/L比（1.26±0.48）mg/L,P〈0.05]。肺癌患者血清Cys C水平与性别、年龄及肺癌组织学类型无关。结论血清Cys C含量在肺癌患者中明显增高,并与肿瘤的临床分期、淋巴结转移及恶性程度相关,提示血清Cys C水平的变化在肺癌的发生发展过程中起重要作用。

Clinical Significance of Serum Cystatin C in Patients with Non-small Cell Lung Cancer

Objective To investigate the clinical significance of serum cystatin C（Cys C） in patients with non-small cell lung cancer（NSCLC）.Methods The serum level of cystatin C was determined by enzyme linked immunosorbent assay（ELISA） in patients with NSCLC,patients with benign lung diseases,and normal controls.Results The serum level of Cys C in the NSCLC patients was much higher than those in the patients with benign lung diseases and the normal control subjects [（1.47±0.78）mg/L vs.（1.04±0.51）mg/L and（1.06±0.36）mg/L,P0.01].The level of Cys C in the NSCLC patients was significantly related to clinical stage [TNM stage Ⅰ-Ⅱ vs.Ⅲ-Ⅳ：（1.38±0.88）mg/L vs.（1.57±0.79）mg/L],lymph node metastasis [metastatic vs.non-metastatic：（1.83±0.97）mg/L vs.（1.06±0.39）mg/L],and differentiation degree [medium-high differentiation vs.low differentiation：（1.63±0.73）mg/L vs.（1.26±0.48）mg/L]（all P0.05）.However no correlation of Cys C with gender,age,and histological type was revealed（P0.05）.Conclusion Cys C may contribute to the occurrence and development of NSCLC.